AMICH Jorge's profile
avatar

AMICH JorgeORCID_LOGO

  • National Centre for Mycology, Instituto de Salud Carlos III, Madrid, Spain
  • Drug development, Drug resistance, tolerance and persistence, Eukaryotic pathogens/symbionts, Immunity to infections (innate, adaptive), Microbiology of infections, Molecular biology of infections, Pathogenic/Symbiotic Fungi, Resistance/Virulence/Tolerance
  • administrator, manager, recommender

Recommendation:  1

Reviews:  0

Areas of expertise
With more than 15 years of experience, I am an internationally recognized expert in fungal metabolism, virulence determinants, antifungal targets and drug resistance and persistence. I received my PhD in 2010 at the University of Salamanca, Spain. Subsequently, I worked for 5 years as a postdoctoral researcher in two different laboratories in Germany. In 2016, I started my own group as a MRC Career Development Awardee at the University of Manchester, in the Manchester Fungal Infection Group (MFIG). In 2022 I moved to the National Mycology Reference Centre in Madrid, Spain, where I continue my investigations aiming to devise novel antifungal strategies and diagnostic mechanisms.

Recommendation:  1

21 Jul 2022
article picture

Structural variation turnovers and defective genomes: key drivers for the in vitro evolution of the large double-stranded DNA koi herpesvirus (KHV)

Understanding the in vitro evolution of Cyprinid herpesvirus 3 (CyHV-3), a story of structural variations that can lead to the design of attenuated virus vaccines

Recommended by based on reviews by Lucie Cappuccio and Veronique Hourdel

Structural variations (SVs) play a key role in viral evolution, and therefore they are also important for infection dynamics. However, the contribution of structural variations to the evolution of double-stranded viruses is limited. This knowledge can help to understand the population dynamics and might be crucial for the future development of viral attenuated vaccines.

In this study, Fuandila et al (1) use the Cyprinid herpesvirus 3 (CyHV-3), commonly known as koi herpesvirus (KHV), to investigate the variability and contribution of structural variations (SV) for viral evolution after 99 passages in vitro. This virus, with the largest genome among herperviruses, causes a lethal infection in common carp and koi associated with mortalities up to 95% (2). Interestingly, KHV infections are caused by haplotype mixtures, which possibly are a source of genome diversification, but make genomic comparisons more difficult.

The authors have used ultra-deep long-read sequencing of two passages, P78 and P99, which were previously described to have differences in virulence. They have found a surprisingly high and wide distribution of SVs along the genome, which were enriched in inversion and deletion events and that often led to defective viral genomes. Although it is known that these defective viral genomes negatively impact viral replication, their implications for virus persistence are still unclear.

Subsequently, the authors concentrated on the virulence-relevant region ORF150, which was found to be different in P78 (deletion in 100% of the reads) and P99 (reference-like haplotype). To understand this loss and gain of full ORF150, they searched for SV turn-over in 10 intermediate passages. This analysis revealed that by passage 10 deleted and inverted (attenuated) haplotypes had already appeared, steadily increased frequency until P78, and then completely disappeared between P78 and P99. This is a striking result that raises new questions as to how this clearance occurs, which is really important as these reversions may result in undesirable increases in virulence of live-attenuated vaccines.

We recommend this preprint because its use of ultra-deep long-read sequencing has permitted to better understand the role of SV diversity and dynamics in viral evolution. This study shows an unexpectedly high number of structural variations, revealing a novel source of virus diversification and confirming the different mixtures of haplotypes in different passages, including the gain of function. This research provides basic knowledge for the future design of live-attenuated vaccines, to prevent the reversion to virulent viruses. 

References

(1)  Fuandila NN, Gosselin-Grenet A-S, Tilak M-K, Bergmann SM, Escoubas J-M, Klafack S, Lusiastuti AM, Yuhana M, Fiston-Lavier A-S, Avarre J-C, Cherif E (2022) Structural variation turnovers and defective genomes: key drivers for the in vitro evolution of the large double-stranded DNA koi herpesvirus (KHV). bioRxiv, 2022.03.10.483410, ver. 4 peer-reviewed and recommended by Peer Community in Infections. https://doi.org/10.1101/2022.03.10.483410

(2)  Sunarto A, McColl KA, Crane MStJ, Sumiati T, Hyatt AD, Barnes AC, Walker PJ. Isolation and characterization of koi herpesvirus (KHV) from Indonesia: identification of a new genetic lineage. Journal of Fish Diseases, 34, 87-101. https://doi.org/10.1111/j.1365-2761.2010.01216.x 

avatar

AMICH JorgeORCID_LOGO

  • National Centre for Mycology, Instituto de Salud Carlos III, Madrid, Spain
  • Drug development, Drug resistance, tolerance and persistence, Eukaryotic pathogens/symbionts, Immunity to infections (innate, adaptive), Microbiology of infections, Molecular biology of infections, Pathogenic/Symbiotic Fungi, Resistance/Virulence/Tolerance
  • administrator, manager, recommender

Recommendation:  1

Reviews:  0

Areas of expertise
With more than 15 years of experience, I am an internationally recognized expert in fungal metabolism, virulence determinants, antifungal targets and drug resistance and persistence. I received my PhD in 2010 at the University of Salamanca, Spain. Subsequently, I worked for 5 years as a postdoctoral researcher in two different laboratories in Germany. In 2016, I started my own group as a MRC Career Development Awardee at the University of Manchester, in the Manchester Fungal Infection Group (MFIG). In 2022 I moved to the National Mycology Reference Centre in Madrid, Spain, where I continue my investigations aiming to devise novel antifungal strategies and diagnostic mechanisms.